STAR LAKE SCIENCE(SH:600866)2020-10-26 16:00Financial Performance - Net profit attributable to shareholders was ¥109,827,909.42, representing a decrease of 9.91% year-on-year[19]. - Operating revenue for the period was ¥806,030,513.49, down 4.58% from the same period last year[19]. - The net profit after deducting non-recurring gains and losses was ¥101,473,513.42, a decrease of 13.38% year-on-year[19]. - Basic earnings per share were ¥0.1486, down 9.94% from ¥0.1650 in the previous year[19]. - The company reported a net loss of CNY -363,574,648.42, an improvement from the previous year's loss of CNY -473,402,557.84, indicating a reduction in losses[38]. - The company reported a net loss of CNY -213,222,014.25, an improvement from a loss of CNY -260,084,233.37[44]. - The company’s net profit for the first three quarters of 2020 was ¥109.83 million, down 10% from ¥121.90 million in the same period of 2019[50]. - The net profit for Q3 2020 was ¥26.18 million, a decline of 42% from ¥44.80 million in Q3 2019[50]. - The company’s total operating revenue for the first three quarters of 2020 was ¥806.03 million, a decrease of 4.6% from ¥844.69 million in the same period of 2019[48]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,406,897,119.61, an increase of 13.74% compared to the end of the previous year[19]. - The company’s total liabilities reached CNY 776,784,442.96, up from CNY 595,947,634.93, marking an increase of approximately 30.2%[38]. - The company’s total equity attributable to shareholders rose to CNY 1,630,112,676.65 from CNY 1,520,284,767.23, reflecting an increase of about 7.2%[38]. - Total liabilities decreased to CNY 404,996,653.74 from CNY 502,295,070.57, representing a reduction of approximately 19.4%[44]. - The company’s total equity increased to CNY 1,780,485,627.60 from CNY 1,733,623,408.48, reflecting a growth of about 2.7%[44]. - The company’s cash and cash equivalents slightly decreased from CNY 150,443,921.76 to CNY 150,371,853.72, a reduction of about 0.05%[42]. Cash Flow - Net cash flow from operating activities was ¥125,274,513.18, a decline of 30.30% compared to the previous year[19]. - Cash flow from operating activities generated a net amount of ¥125.27 million, down 30.3% from ¥179.75 million in the previous year[59]. - Net cash flow from operating activities was CNY 111,764,162.21, down from CNY 131,002,260.79 year-over-year, reflecting a decline of 14.5%[64]. - Cash outflow from investment activities totaled CNY 27,585,038.04, significantly lower than CNY 340,002,790.75 in the previous year, indicating a reduction of 91.9%[64]. - The ending cash and cash equivalents balance was CNY 150,371,853.72, compared to CNY 164,938,600.75 at the end of the previous year, a decrease of 8.8%[64]. Shareholder Information - Total number of shareholders at the end of the reporting period is 56,148[24]. - The largest shareholder, Guangdong Guangxin Holdings Group, holds 122,812,906 shares, representing 16.62% of total shares[24]. Investments and Projects - The company plans to invest up to CNY 680 million in the first phase of the Zhaodong Bio-fermentation Industrial Park project, which includes a production line for nucleotides[31]. - The company has completed most of the structural engineering and equipment installation for the Zhaodong project, although the overall progress has been delayed due to the COVID-19 pandemic[31]. - Long-term borrowings increased by 728.78% to ¥174,044,175.75, reflecting new loans for the Zhaodong Fermentation Industrial Park project[27]. Research and Development - Research and development expenses increased to ¥15.99 million in Q3 2020, up 21% from ¥13.18 million in Q3 2019[48]. - The company plans to continue focusing on R&D to drive future growth, as indicated by the increase in R&D expenses[48].